Detailed information for compound 603754
Basic information
Technical information
- TDR Targets ID: 603754
- Name: 2-[[4-(2,5-dimethylphenyl)piperazin-1-yl]meth yl]-4-methoxyphenol
- MW: 326.433 | Formula: C20H26N2O2
-
H donors: 1
H acceptors: 1
LogP: 3.7
Rotable bonds: 4
Rule of 5 violations (Lipinski): 1 - SMILES: COc1ccc(c(c1)CN1CCN(CC1)c1cc(C)ccc1C)O
- InChi: 1S/C20H26N2O2/c1-15-4-5-16(2)19(12-15)22-10-8-21(9-11-22)14-17-13-18(24-3)6-7-20(17)23/h4-7,12-13,23H,8-11,14H2,1-3H3
- InChiKey: DKVXRKYPHXFNPB-UHFFFAOYSA-N
Network
Hover on a compound node to display the structore
Synonyms
- 2-[[4-(2,5-dimethylphenyl)piperazin-1-yl]methyl]-4-methoxy-phenol
- 2-[[4-(2,5-dimethylphenyl)-1-piperazinyl]methyl]-4-methoxyphenol
- Oprea1_306034
Targets
Known targets for this compound
No curated genes were found associated with this compound
Predicted pathogen targets for this compound
By orthology
No druggable targets predicted by orthology data
By sequence similarity to non orthologous known druggable targets
No druggable targets predicted by sequence similarity
Obtained from network model
Ranking Plot
Putative Targets List
| Species | Potential target | Raw | Global | Species |
|---|---|---|---|---|
| Echinococcus granulosus | cadherin EGF LAG seven pass G type receptor | 0.0048 | 0.0295 | 0.0371 |
| Brugia malayi | RNA recognition motif domain containing protein | 0.013 | 0.5126 | 0.4978 |
| Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.009 | 0.2787 | 0.3508 |
| Loa Loa (eye worm) | hypothetical protein | 0.006 | 0.1019 | 0.0746 |
| Loa Loa (eye worm) | hypothetical protein | 0.0151 | 0.6335 | 0.6224 |
| Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.009 | 0.2787 | 0.3508 |
| Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.5126 | 0.4978 |
| Echinococcus multilocularis | GA binding protein alpha chain | 0.007 | 0.1617 | 0.2035 |
| Echinococcus multilocularis | Transcription factor, JmjC domain containing protein | 0.01 | 0.3385 | 0.4261 |
| Echinococcus granulosus | Transcription factor JmjC domain containing protein | 0.01 | 0.3385 | 0.4261 |
| Brugia malayi | RNA binding protein | 0.013 | 0.5126 | 0.4978 |
| Loa Loa (eye worm) | RNA recognition domain-containing protein domain-containing protein | 0.013 | 0.5126 | 0.4978 |
| Loa Loa (eye worm) | pigment dispersing factor receptor c | 0.0151 | 0.6335 | 0.6224 |
| Brugia malayi | Ets-domain containing protein | 0.007 | 0.1617 | 0.1362 |
| Schistosoma mansoni | hypothetical protein | 0.0103 | 0.3539 | 0.3343 |
| Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.5126 | 0.4978 |
| Echinococcus multilocularis | GPCR, family 2 | 0.0048 | 0.0295 | 0.0371 |
| Brugia malayi | GTP-binding regulatory protein Gs alpha-S chain, putative | 0.009 | 0.2787 | 0.2568 |
| Echinococcus multilocularis | diuretic hormone 44 receptor GPRdih2 | 0.0048 | 0.0295 | 0.0371 |
| Echinococcus multilocularis | cadherin EGF LAG seven pass G type receptor | 0.0048 | 0.0295 | 0.0371 |
| Brugia malayi | Corticotropin releasing factor receptor 2 precursor, putative | 0.0151 | 0.6335 | 0.6224 |
| Schistosoma mansoni | hypothetical protein | 0.0178 | 0.7945 | 0.7882 |
| Loa Loa (eye worm) | D-ets-4 DNA binding domain-containing protein | 0.007 | 0.1617 | 0.1362 |
| Schistosoma mansoni | hypothetical protein | 0.0178 | 0.7945 | 0.7882 |
| Echinococcus granulosus | tar DNA binding protein | 0.013 | 0.5126 | 0.6451 |
| Loa Loa (eye worm) | fli-1 protein | 0.0213 | 1 | 1 |
| Brugia malayi | TAR-binding protein | 0.013 | 0.5126 | 0.4978 |
| Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.009 | 0.2787 | 0.2568 |
| Echinococcus multilocularis | tar DNA binding protein | 0.013 | 0.5126 | 0.6451 |
| Brugia malayi | Ets-domain containing protein | 0.007 | 0.1617 | 0.1362 |
| Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.5126 | 0.4978 |
| Schistosoma mansoni | gabp alpha | 0.007 | 0.1617 | 0.1362 |
| Loa Loa (eye worm) | hypothetical protein | 0.0053 | 0.058 | 0.0294 |
| Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.009 | 0.2787 | 0.2568 |
| Echinococcus granulosus | geminin | 0.0178 | 0.7945 | 1 |
| Brugia malayi | Calcitonin receptor-like protein seb-1 | 0.0151 | 0.6335 | 0.6224 |
| Echinococcus granulosus | diuretic hormone 44 receptor GPRdih2 | 0.0048 | 0.0295 | 0.0371 |
| Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.5126 | 0.4978 |
| Echinococcus granulosus | guanine nucleotide binding protein Gs subunit | 0.009 | 0.2787 | 0.3508 |
| Schistosoma mansoni | ets-related | 0.0213 | 1 | 1 |
| Loa Loa (eye worm) | hypothetical protein | 0.0103 | 0.3539 | 0.3343 |
| Loa Loa (eye worm) | RNA binding protein | 0.013 | 0.5126 | 0.4978 |
| Brugia malayi | latrophilin 2 splice variant baaae | 0.0103 | 0.3539 | 0.3343 |
| Echinococcus multilocularis | guanine nucleotide binding protein G(s) subunit | 0.009 | 0.2787 | 0.3508 |
| Schistosoma mansoni | jumonji domain containing protein | 0.008 | 0.2175 | 0.1938 |
| Echinococcus multilocularis | geminin | 0.0178 | 0.7945 | 1 |
| Loa Loa (eye worm) | TAR-binding protein | 0.013 | 0.5126 | 0.4978 |
| Schistosoma mansoni | Guanine nucleotide-binding protein G(s) subunit alpha (Adenylate cyclase-stimulating G alpha protein) | 0.009 | 0.2787 | 0.2568 |
| Echinococcus granulosus | GA binding protein alpha chain | 0.007 | 0.1617 | 0.2035 |
| Loa Loa (eye worm) | GTP-binding regulatory protein Gs alpha-S chain | 0.009 | 0.2787 | 0.2568 |
| Schistosoma mansoni | tar DNA-binding protein | 0.013 | 0.5126 | 0.4978 |
| Loa Loa (eye worm) | jmjC domain-containing protein | 0.0063 | 0.121 | 0.0943 |
| Brugia malayi | jmjC domain containing protein | 0.01 | 0.3385 | 0.3184 |
| Echinococcus granulosus | GPCR family 2 | 0.0048 | 0.0295 | 0.0371 |
Activities
| Activity type | Activity value | Assay description | Source | Reference |
|---|---|---|---|---|
| aqueous solubility, where (a) 0 = extremely low, (b) 1 = very low; (c) 2 = low, (d) 3 = good, (e) 4 = optimal, (f) 5 = very soluble (ADMET) | = 2 | aqueous solubility, where (a) 0 = extremely low, (b) 1 = very low; (c) 2 = low, (d) 3 = good, (e) 4 = optimal, (f) 5 = very soluble | Saint Jude. | 20485428 |
| Compound predicted to be a mutagen in Ames test: 0=false; 1=true (ADMET) | = 0 | TRUE if compound predicted to be a mutagen in an Ames test | Saint Jude. | 20485428 |
| EC50 (functional) | 0.4878 uM | ST_JUDE: Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye | ChEMBL. | 20485428 |
| EC50 (functional) | = 0.49 uM | Plasmodium falciparum K1 EC50 (uM) as measured by SYBR green dye | Saint Jude. | 20485428 |
| EC50 (functional) | 0.5663 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum W2 | ChEMBL. | 20485428 |
| EC50 (functional) | = 0.57 uM | Cytotoxic activity for compound versus Plasmodium falciparum W2 | Saint Jude. | 20485428 |
| EC50 (functional) | 0.6595 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum V1/S | ChEMBL. | 20485428 |
| EC50 (functional) | = 0.66 uM | Cytotoxic activity for compound versus Plasmodium falciparum V1/S | Saint Jude. | 20485428 |
| EC50 (functional) | = 0.7408 uM | Cytotoxic activity for compound versus Plasmodium falciparum Dd2 | Saint Jude. | 20485428 |
| EC50 (functional) | 0.7408 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum Dd2 | ChEMBL. | 20485428 |
| EC50 (functional) | = 0.992 uM | Cytotoxic activity for compound versus Plasmodium falciparum K1 | Saint Jude. | 20485428 |
| EC50 (functional) | 0.992 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum K1 | ChEMBL. | 20485428 |
| EC50 (functional) | = 1.23 uM | Cytotoxic activity for compound versus Plasmodium falciparum D10 transfected with yeast DHOD | Saint Jude. | 20485428 |
| EC50 (functional) | 1.2345 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum D10 transfected with yeast DHOD | ChEMBL. | 20485428 |
| EC50 (functional) | = 1.293 uM | Cytotoxic activity for compound versus Plasmodium falciparum SB-A6 | Saint Jude. | 20485428 |
| EC50 (functional) | 1.293 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum SB-A6 | ChEMBL. | 20485428 |
| EC50 (functional) | = 1.37 uM | Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye | Saint Jude. | 20485428 |
| EC50 (functional) | 1.371 uM | ST_JUDE: Plasmodium falciparum 3D7 EC50 (uM) as measured by SYBR green dye | ChEMBL. | 20485428 |
| EC50 (functional) | = 2.0664 uM | Differential activity in the presence of antimalarial chloroquine | Saint Jude. | 20485428 |
| EC50 (functional) | = 2.2035 uM | Cytotoxic activity for compound versus Plasmodium falciparum 3D7 | Saint Jude. | 20485428 |
| EC50 (functional) | 2.2035 uM | ST_JUDE: Cytotoxicity against Plasmodium falciparum 3D7 | ChEMBL. | 20485428 |
| EC50 (functional) | = 3.4693 uM | Differential activity in the presence of antimalarial atovaquone | Saint Jude. | 20485428 |
| EC50 (functional) | = 3.6465 uM | Differential activity in the presence of antimalarial artemisinin | Saint Jude. | 20485428 |
| EC50 (functional) | > 9.108 uM | Differential activity in the presence of antimalarial mefloquine | Saint Jude. | 20485428 |
| EC50 (binding) | > 10 uM | Plasmodium falciparum dihydroorotate dehydrogenase inhibition assay | Saint Jude. | 20485428 |
| EC50 (functional) | > 15.18 uM | ST_JUDE: Cytotoxicity using Alamar Blue to measure viability of Leishmania major | ChEMBL. | 20485428 |
| EC50 (functional) | > 19.4304 uM | Cytotoxic activity for compound versus Toxoplasma gondii | Saint Jude. | 20485428 |
| EC50 (functional) | > 19.4304 uM | ST_JUDE: Growth inhibition of to Toxoplasma gondii, in human U-2OS cells, as measured by luciferase. | ChEMBL. | 20485428 |
| EC50 (functional) | = 24 uM | hemozoin polymerization inhibition assay. EC50 from hemozoin assay were approximately derived based on 3 point dose response | Saint Jude. | 20485428 |
| EC50 (functional) | > 34.0032 uM | Cytotoxic activity for compound versus Trypanosoma brucei | Saint Jude. | 20485428 |
| EC50 (functional) | = 34.0032 uM | Cytotoxic activity for compound versus Leishmania major | Saint Jude. | 20485428 |
| EC50 (functional) | > 34.0032 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of Trypanosoma brucei | ChEMBL. | 20485428 |
| EC50 (functional) | > 35.4605 uM | Cytotoxic activity for compound versus human forskin fibroblast cells | Saint Jude. | 20485428 |
| EC50 (functional) | > 35.4605 uM | Cytotoxic activity for compound versus human epithelial hepatocellular carcinoma cells | Saint Jude. | 20485428 |
| EC50 (functional) | > 35.4605 uM | Cytotoxic activity for compound versus human epithelial embryonic kidney cells | Saint Jude. | 20485428 |
| EC50 (functional) | > 35.4605 uM | Cytotoxic activity for compound versus human Burkitt's lymphoma lymphoblast cells | Saint Jude. | 20485428 |
| EC50 | > 35.4605 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial hepatocellular carcinoma cells (HepG2) | ChEMBL. | 20485428 |
| EC50 | > 35.4605 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human epithelial embryonic kidney cells (HEK293) | ChEMBL. | 20485428 |
| EC50 | > 35.4605 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human foreskin fibroblast cells (BJ) | ChEMBL. | 20485428 |
| EC50 | > 35.4605 uM | ST_JUDE: Cytotoxicity using luciferase to measure ATP as an indicator of the viability of human Burkitt''s lymphoma lymphoblast cells (Raji) | ChEMBL. | 20485428 |
| EC50 (binding) | > 50 uM | Plasmodium falciparum falcipain 2 inhibition assay | Saint Jude. | 20485428 |
| Inhibition (functional) | = 2 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 LDH activity, using an LDH reporter assay. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition (functional) | = 2.89 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGT2 that are glucose transport deficient and complemented with the L. Mexicana glucose transporter 2. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 2.93 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmGLUT1 that are glucose transport deficient and complemented with the human glucose transporter GLUT1. Activity is measured by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 3 % | ST_JUDE_LEISH: Cytotoxicity at 2uM final concentration against transgenic Leishmania Mexicana promastigotes LmPfHT that are glucose transport deficient and complemented with the Plasmodium falciparum hexose transporter. Activity is measured by by DNA content using SYBR green in vitro | ChEMBL. | No reference |
| Inhibition (functional) | = 7 % | GSK_TCMDC: Percent inhibition of human HepG2 cell line. Test compounds present at 10uM. | ChEMBL. | 20485427 |
| Inhibition (functional) | = 86 % | GSK_TCMDC: Inhibition of Plasmodium falciparum Dd2 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition (functional) | = 90 % | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole red blood cells, using parasite LDH activity as an index of growth. Test compounds present at 2uM | ChEMBL. | 20485427 |
| Inhibition frequency index (IFI) (functional) | = 0.92 | Inhibition Frequency Index (IFI) | GSK. | 20485427 |
| LD50 (ADMET) | = 1.04 g kg-1 | rat oral acute median lethal dose (g/kg) | Saint Jude. | 20485428 |
| passive intestinal absorption level, where (a) 0 good; (b) 1 = moderate; (c) 2 = poor, (d) 3 = very poor (ADMET) | = 0 | passive intestinal absorption level, where (a) 0 good; (b) 1 = moderate; (c) 2 = poor, (d) 3 = very poor | Saint Jude. | 20485428 |
| Percent growth inhibition (functional) | = 2 % | Percent inhibition of P. falciparum lactate dehydrogenase activity (at 2 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 7 % | Percent inhibition of HepG2 growth (at 10 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 86 % | Percent inhibition of P. falciparum Dd2 growth (at 2 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 90 % | Percent inhibition of P. falciparum 3D7 growth (at 2 uM) | GSK. | 20485427 |
| Percent growth inhibition (functional) | = 95.1 % | Plasmodium falciparum 3D7 % growth inhibition at 7uM as measured by SYBR green dye | Saint Jude. | 20485428 |
| Percent growth inhibition (functional) | = 98.8 % | Plasmodium falciparum 3D7 % growth inhibition at 7uM as measured by YOYO-3 red dye | Saint Jude. | 20485428 |
| XC50 (functional) | = 6 | XC50 determination of P. falciparum 3D7 growth | GSK. | 20485427 |
| XC50 (functional) | = 1.00621 uM | GSK_TCMDC: Inhibition of Plasmodium falciparum 3D7 in whole erythrocytes, using parasite LDH activity as an index of growth. | ChEMBL. | 20485427 |
Phenotypes
Whole-cell/tissue/organism interactions
| Species name | Source | Reference | Is orphan |
|---|---|---|---|
| Plasmodium falciparum | ChEMBL23 | 20485428 | |
| Leishmania major | ChEMBL23 | 20485428 | |
| Toxoplasma gondii | ChEMBL23 | 20485428 |
Many chemical entities in TDR Targets come from high-throughput screenings with whole cells or tissue samples, and not all assayed compounds have been tested against a single a single target protein, probably because they get ruled out during screening process. Even if these compounds may have not been of interest in the original screening, they may come as interesting leads for other screening assays. Furthermore, we may be able to propose drug-target associations using chemical similarities and network patterns.
Annotated phenotypes:
We have no manually annotated phenotypes for this drug.
What does this mean? / Care to help?
In TDR Targets, information about phenotypes that are caused by
drugs, or by genetic manipulation of cells (e.g. gene knockouts or
knockdowns) is manually curated from the literature. These
descriptions help to describe the potential of the target for drug
development. If no information is available for this gene or if the
information is incomplete, this may mean that i) the papers
containing this information either appeared after the curation
effort for this organism was carried out or they were inadvertently
missed by curators; or that ii) the curation effort for this
organism has not yet started.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
In any case, if you have information about papers containing relevant validation data for this target, please log in using your TDR Targets username and password and send them to us using the corresponding form in this page (only visible to registered users) or contact us.
External resources for this compound
- ChEMBL: CHEMBL529075
- Search by GSK
- Search by Saint Jude
Bibliographic References
1 literature reference was collected for this gene.
If you have references for this compound, please enter them in a user comment (below) or Contact us.